National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Understanding Cancer Series: Blood Stem Cell Transplants
< Back to Main
In English     En español
    Posted: 09/01/2006    Reviewed: 09/01/2006
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Slide 4  :  Blood Stem Cell Transplants: When? <  >  

In patients with blood cancers such as myeloma, leukemia, or lymphoma, the chemotherapy and radiation that kill malignant cells also kill healthy marrow and its resident blood stem cells. Whether the cancer begins in the marrow itself or in lymphoid or other organs, anticancer treatment can deplete much of the body's reserve of blood-forming stem cells. Even patients with noncancerous blood diseases can develop a shortage of blood stem cells, as occurs in life-threatening anemias or immune disorders. In all these cases, a blood stem cell transplant can restore normal hematopoiesis.

Hematopoietic or blood stem cell transplants are also called bone marrow transplants or peripheral blood stem cell transplants, depending upon the location of stem cell collection.

Blood Stem Cell Transplants: When?

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov